Rewiring PD-1/PD-L1 combination therapy via glyco-immune targeting of galectins: Toward clinical translation
{{output}}
Despite advances in PD-1/PD-L1 combination therapies, clinical benefits remain limited and toxicity is significant. Galectins, a family of β-galactoside-binding lectins, have emerged as mechanistically distinct, multimodal targets with the potential to addres... ...
